

RESEARCH

Open Access



Association between lipid accumulation product (LAP) index and self-reported oral health outcomes: a cross-sectional study

Li Shuning^{1*}, Yang Wei¹, Fan Xuhui¹, Dong Jianfeng¹ and Liu Jilun¹

Abstract

Background Lipid Accumulation Product (LAP) is a biomarker associated with excessive lipid accumulation and various metabolic diseases. Despite the well-established link between oral and systemic health, the association between LAP and oral health remains largely unexplored.

Methods Data from 7,124 participants aged over 18 years from the National Health and Nutrition Examination Survey (NHANES) between 2009 and 2014 were analyzed. Multivariate logistic regression models were applied to evaluate the independent association between LAP and self-reported oral health outcomes, adjusting for potential confounders.

Results There was a significant correlation between increasing LAP levels and deteriorating oral health status ($\beta = 0.26$, 95% CI: 0.20 to 0.32, $P < 0.0001$). Subgroup analyses revealed that the negative correlation between LAP and self-reported oral health outcomes was more pronounced in younger individuals and those with higher education levels. A non-linear relationship was identified, with oral health deteriorating significantly as LAP increased up to a threshold of 83, after which the relationship became non-significant.

Conclusions This study demonstrates a robust association between LAP and self-reported oral health outcomes, suggesting that LAP could be a reliable indicator for assessing oral health status. The findings highlight the importance of targeted health interventions for populations with higher LAP indices to prevent oral health deterioration and potential systemic health issues.

Keywords NHANES, LAP, Oral health, Cross-sectional study

*Correspondence:

Li Shuning
lishuning94@foxmail.com

¹The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Introduction

Waist circumference (WC) and blood triglycerides (TG) are essential indicators for evaluating the risk of excessive lipid accumulation in adults, with the LAP serving as a biomarker for this assessment. The formula for LAP is $LAP = (WC - 65) \times TG$ for men and $LAP = (WC - 58) \times TG$ for women, where WC represents waist circumference (cm) and TG denotes serum triglycerides (mmol/L) [1]. Research indicates that LAP is linked to several illnesses, including polycystic ovarian syndrome (PCOS) [2], metabolic syndrome [3], diabetes [4, 5], cardiovascular diseases [6, 7], mild cognitive impairment [8], hepatic steatosis [9], and sarcopenia [10]. This highlights the importance of LAP in identifying the risk of diseases associated with excessive lipid accumulation.

Oral health is not merely a local tissue concern but also intricately linked to systemic disease progression. Emerging evidence demonstrates that oral inflammation triggers chronic low-grade systemic inflammation through microorganism-host interactions, thereby contributing to metabolic disorders. A bidirectional vicious cycle exists between diabetes [11] and periodontitis, exemplifying this interconnection. Notably, significant associations have been established between oral inflammatory conditions and various systemic pathologies, including metabolic syndrome [12], rheumatoid arthritis [13], osteoporosis [14], and certain malignancies [15, 16]. The underlying mechanisms involve: (1) IL-6 and TNF- α -mediated exacerbation of insulin resistance [17]; (2) oxidative stress-induced vascular endothelial dysfunction [18]; and (3) systemic immune activation through bacteremia caused by oral pathogens such as *Porphyromonas gingivalis* [19]. These pathways collectively underscore the pivotal role of oral health as a critical modulator of systemic health.

LAP has demonstrated strong diagnostic capabilities in metabolic diseases [3, 20, 21] and is closely associated with systemic inflammation, obesity, and other systemic disorders. These factors, along with the oral microbiome, are well-established risk factors for poor oral health. Despite the clear overlap between LAP-related diseases and those associated with oral health, the role of LAP in oral health outcomes remains unexplored. This gap in the literature underscores the need for further investigation. Therefore, this study aims to explore the relationship between LAP and oral health, enhancing our understanding and potentially establishing LAP as a diagnostic tool for assessing oral health risks.

Methods

Data sources and study population

NHANES collected data on exposures and their outcomes. This data was collected throughout three consecutive cycles from 2009 to 2014. The data were collected

through health interviews conducted at participants' residences, health checks carried out at mobile testing centres (MECs), and laboratory samples. There was no need for a supplementary ethical review for this manuscript, as NHANES underwent an ethical review by the National Ethical Review Board for Research in Health Statistics [22]. The missing data were imputed using multiple imputation.

The study initially comprised 30,468 participants from NHANES data collected between 2009 and 2014, incorporating comprehensive self-assessed oral health data of U.S. adults. Participant eligibility was determined based on the following criteria: [1] complete waist circumference data; [2] complete triglyceride data; [3] complete self-assessed oral health information; and [4] age over 18 years. In the end, 7,124 people were involved in the research. Figure 1 illustrates the data filtration process.

Outcome variable

The Oral Health Questionnaire (OHQ) was employed to evaluate the oral health outcomes of individuals, with a five-point scale extending from Excellent to Poor. Oral health status shows progressive deterioration with increasing scores on self-reported oral health outcomes. These metrics have been increasingly employed in population-based research to evaluate both systemic diseases and oral health conditions in recent years. Previous study has established the strong validity of self-reported oral health outcomes and evaluations of periodontal disease in extensive populations [23–25]. The outcome of professional dental examinations is comparable to the reliability and validity of OHQ [26, 27]. Collectively, self-reported oral health outcomes demonstrate significant predictive value for oral health status, highlighting their efficacy in large-scale epidemiological investigations.

Confounding variables

This study included the following covariates: gender, age, race, education level, ratio of family income to poverty (RIP), diabetes, hypertension, coronary heart disease, hypercholesterolemia, gout, stroke, cancer or malignancy, alcohol use, and cigarette use. Based on tertiles, age was divided into three categories. The participant's diabetes status was categorized into three categories: yes, no, or borderline, depending on whether a physician had diagnosed the condition. Cigarette usage was classified into three categories: never smokers, defined as individuals who have smoked fewer than 100 cigarettes in their lifetime; former smokers, who have smoked more than 100 cigarettes but are currently abstinent; and current smokers, who have smoked more than 100 cigarettes and continue to smoke [28]. Alcohol consumption was similarly categorized into three groups: non-drinkers, who do not consume alcohol; moderate drinkers, characterized




Fig. 1 Flowchart of participant selection. NHANES, National Health and Nutrition Examination Survey; WC, waist circumference; TG, triglycerides; OHQ, Oral Health Questionnaire

as men consuming 14 or fewer drinks per week or 5 or fewer drinks on any single day, and women consuming 7 or fewer drinks per week or 5 or fewer drinks on any single day; and heavy drinkers, defined as men consuming more than 14 drinks per week or 5 or more drinks on any single day at least once in the past year, and women consuming more than 7 drinks per week or 5 or more drinks on any single day at least once in the past year [29].

Statistical analysis

The statistical analysis of the results was performed using R software (R 4.2.1) in combination with Empower Stats

4.1. The study utilized multivariate logistic regression to investigate the independent association between LAP and self-reported oral health outcomes. Three models were employed: an unadjusted model; a partial adjustment model adjusted for gender, age, race, education level, and the RIP; and fully adjusted model adjusted for gender, age, race, education level, RIP, diabetes, hypertension, coronary heart disease, hypercholesterolemia, gout, stroke, cancer or malignancy, alcohol use and cigarette use. Interaction tests, subgroup analyses, threshold effect experiments, and smoothed curve fitting were conducted

to explore the multidimensional relationship between self-reported oral health outcomes and LAP.

Results

Baseline characteristics of the population

The Table 1 displays the fundamental features of the research population. This study conducted a comparative analysis of 7124 participants stratified into three groups based on the LAP index (LAPT1, LAPT2, and LAPT3). There were significant age differences among the three groups, with the LAPT1 group having an average age of 35.18 years, while the LAPT3 group had an average age of 51.56 years ($P < 0.001$). The LAPT3 group exhibited a considerably higher percentage of individuals with lesser education levels in terms of educational attainment ($P < 0.001$).

The prevalence of chronic diseases also differed significantly, with rates of diabetes, hypertension, hypercholesterolemia, and gout rising with an increasing LAP index. Specifically, the incidence of diabetes increased from 2.60% in the LAPT1 group to 18.49% in the LAPT3 group ($P < 0.001$).

In terms of lifestyle behaviors, the percentage of current smokers increased substantially from 13.22% in LAPT1 to 20.33% in LAPT3 ($P < 0.001$), while the percentage of heavy drinkers did not see a statistically significant increase ($P = 0.010$). In all three groups, oral health deteriorated progressively with increasing LAP levels ($P < 0.001$).

In summary, participants with different LAP indices exhibited significant variations in health status and lifestyle factors, highlighting the importance of targeted health interventions for populations with higher LAP indices.

Univariate analysis

This study investigated the impact of various factors on self-reported oral health outcomes using univariate analysis, with the results summarized in Table 2. The base-10 logarithm was employed to transform LAP in order to guarantee the accuracy of the results and the feasibility of data analysis. The analysis demonstrated a substantial correlation between deteriorating oral health status and elevated levels of LAP ($P < 0.0001$). Additionally, females exhibited poorer oral health compared to males ($P = 0.0069$). Moreover, higher age, specific racial backgrounds, and lower educational levels were significantly correlated with deteriorating oral health ($P < 0.0001$). Oral health was also significantly impacted by chronic conditions, including hypertension, coronary heart disease, diabetes, and hypercholesterolemia ($P < 0.0001$). In terms of smoking behavior, current smokers showed significantly worse oral health status ($P < 0.0001$). Conversely, alcohol use, as well as cancer and malignancy,

did not show a significant correlation with oral health (P were 0.9458 and 0.0530, respectively).

Relationship between LAP and self-reported oral health outcomes

In order to assess the correlation between self-reported oral health outcomes and LAP, we implemented a multivariable logistic regression analysis (Table 3). The unadjusted model demonstrated a substantial correlation between self-reported oral health outcomes and the log-transformed LAP, with a coefficient of $\beta = 0.42$ (95% CI: 0.37 to 0.48, $P < 0.0001$). The result in the partially adjusted model indicated a modest change ($\beta = 0.31$, 95% CI: 0.25 to 0.37, $P < 0.0001$), whereas in the fully adjusted model, $\beta = 0.26$ (95% CI: 0.20 to 0.32, $P < 0.0001$). The log-transformed LAP was classified into tertiles for sensitivity analysis, and a comparable trend was observed ($P < 0.0001$). With an increase in LAP, the oral health status significantly declines.

The non-linear relationship between LAP and self-reported oral health outcomes

A nonlinear relationship between LAP and self-reported oral health outcomes was identified after adjusting for various confounding factors (Fig. 2). The folding point was identified as 83 through threshold effect analysis (Table 4). When LAP are below 83, there is a significant deterioration in oral health as LAP increases ($P < 0.0001$); conversely, when LAP exceed 83, the relationship between LAP and oral health becomes non-significant ($P = 0.1648$).

The results of subgroup analyses

The test for interactions was significant for age, education level, and gout (P for interaction < 0.05), as illustrated in Fig. 3, while it was not significant for gender, race, RIP, diabetes, hypertension, coronary heart disease, hypercholesterolemia, stroke, cancer or malignancy, alcohol use, and cigarette use (P for interaction = 0.1995, 0.6675, 0.3864, 0.3327, 0.6608, 0.4353, 0.57, 0.101, 0.3073, 0.1135, and 0.0605, respectively). Younger individuals and those with higher levels of education exhibited a more pronounced negative correlation between self-reported oral health outcomes and LAP. Additionally, this negative association was significant in participants without gout, whereas it was not significant in those with gout. The visualized results of the subgroup analysis are presented in the Supplementary Material 1.

Discussion

No studies have yet been conducted to establish an association between oral health and LAP. Both oral health issues and several metabolic disorders share inflammation as a common etiology. This study involved 7,124

Table 1 Characterization of the study population

Variables	LAPT1	LAPT2	LAPT3	P-value
N	2655	2655	2656	
Age	35.18 ± 19.73	49.78 ± 18.50	51.56 ± 16.58	< 0.001
RIP	2.41 ± 1.63	2.52 ± 1.59	2.26 ± 1.53	< 0.001
Gender				0.351
Male	1268 (47.76%)	1318 (49.64%)	1308 (49.25%)	
Female	1387 (52.24%)	1337 (50.36%)	1348 (50.75%)	
Race				< 0.001
Mexican American	315 (11.86%)	376 (14.16%)	485 (18.26%)	
Other Hispanic	232 (8.74%)	281 (10.58%)	304 (11.45%)	
Non-Hispanic White	937 (35.29%)	1102 (41.51%)	1253 (47.18%)	
Non-Hispanic Black	680 (25.61%)	562 (21.17%)	405 (15.25%)	
Other Race	491 (18.49%)	334 (12.58%)	209 (7.87%)	
Education Level				< 0.001
Less Than 9th Grade	121 (4.56%)	258 (9.72%)	315 (11.86%)	
9-11th Grade	214 (8.06%)	342 (12.88%)	443 (16.68%)	
High School Grad/GED or Equivalent	660 (24.86%)	606 (22.82%)	644 (24.25%)	
Some College or AA degree	894 (33.67%)	786 (29.60%)	787 (29.63%)	
College Graduate or above	766 (28.85%)	663 (24.97%)	467 (17.58%)	
Diabetes				< 0.001
YES	69 (2.60%)	279 (10.51%)	491 (18.49%)	
NO	2562 (96.50%)	2311 (87.04%)	2074 (78.09%)	
Borderline	24 (0.90%)	65 (2.45%)	91 (3.43%)	
Hypertension				< 0.001
YES	390 (14.69%)	920 (34.65%)	1299 (48.91%)	
NO	2265 (85.31%)	1735 (65.35%)	1357 (51.09%)	
Coronary Heart Disease				< 0.001
YES	37 (1.39%)	110 (4.14%)	123 (4.63%)	
NO	2618 (98.61%)	2545 (95.86%)	2533 (95.37%)	
Hypercholesterolemia				< 0.001
YES	342 (12.88%)	913 (34.39%)	1205 (45.37%)	
NO	2313 (87.12%)	1742 (65.61%)	1451 (54.63%)	
Gout				< 0.001
YES	303 (11.41%)	673 (25.35%)	872 (32.83%)	
NO	2352 (88.59%)	1982 (74.65%)	1784 (67.17%)	
Stroke				< 0.001
YES	51 (1.92%)	91 (3.43%)	99 (3.73%)	
NO	2604 (98.08%)	2564 (96.57%)	2557 (96.27%)	
Cancer Or Malignancy				< 0.001
YES	141 (5.31%)	241 (9.08%)	265 (9.98%)	
NO	2514 (94.69%)	2414 (90.92%)	2391 (90.02%)	
Alcohol Use				0.01
Never drinking	291 (10.96%)	338 (12.73%)	369 (13.89%)	
Moderate drinking	2289 (86.21%)	2245 (84.56%)	2198 (82.76%)	
Heavy drinking	75 (2.82%)	72 (2.71%)	89 (3.35%)	
Cigarette Use				< 0.001
Never smoker	1435 (54.05%)	1447 (54.50%)	1343 (50.56%)	
Former smoker	869 (32.73%)	737 (27.76%)	773 (29.10%)	
Current smoker	351 (13.22%)	471 (17.74%)	540 (20.33%)	
Self-reported oral health outcomes				< 0.001
Excellent	409 (15.40%)	277 (10.43%)	235 (8.85%)	
Very good	678 (25.54%)	560 (21.09%)	465 (17.51%)	
Good	928 (34.95%)	1005 (37.85%)	992 (37.35%)	

Table 1 (continued)

Variables	LAPT1	LAPT2	LAPT3	P-value
Fair	476 (17.93%)	558 (21.02%)	624 (23.49%)	
Poor	164 (6.18%)	255 (9.60%)	340 (12.80%)	

Results in table: Mean ± SD / N(%)

participants. The results indicate a robust and significant correlation between LAP and the deterioration of oral health status after adjusting for various confounding factors ($\beta = 0.26$, 95% CI: 0.20 to 0.32, $P < 0.0001$). Subgroup analyses also demonstrated consistent patterns. The study indicates that LAP serves as a reliable indicator for assessing oral health, demonstrating exceptional diagnostic accuracy.

LAP is a straightforward and efficient metric of visceral adiposity, closely associated with overall health condition [30]. Higher LAP levels significantly correlate with increased risks of hypertension [31], type 2 diabetes [4, 5], cardiovascular diseases [32], and liver conditions [9]. In populations with PCOS [2], LAP is associated with metabolic disturbances, reflecting impaired glucose tolerance. Moreover, LAP has demonstrated significant predictive value for cardiovascular [33]. It is also significantly associated with subclinical cardiovascular organ damage in elderly populations and is effective in identifying metabolic syndrome in adults with growth hormone deficiency [34]. LAP is an effective tool for diagnosing metabolic diseases and influences changes in systemic inflammatory markers [35, 36], aiding in the identification and management of high-risk populations. This metric is particularly convenient for clinical application, as it can be easily calculated using routine clinical measurements (WC and TG). Therefore, LAP serves not only as an important instrument for assessing individual health risks but also provides a foundation for effective health management and clinical interventions.

Oral diseases are closely linked to various systemic conditions. Firstly, oral health may impact respiratory health by transferring oral microbes to the lungs, thereby increasing the risk of pneumonia [37]. Secondly, periodontal disease has been associated with certain cancers [38, 39]. Most importantly, oral health is related to an increased risk of cardiovascular disease [40] and may exacerbate type 2 diabetes [41] by worsening insulin resistance. As a result, there is a growing awareness of the relationship between oral health and metabolic diseases.

The LAP significantly impacts oral health through several interconnected mechanisms. Firstly, LAP is associated with systemic inflammatory responses, which may exacerbate the progression of periodontal disease by elevating levels of cytokines and chemokines that contribute to periodontal tissue damage [42–45]. Studies have confirmed a significant correlation between inflammatory markers and oral health [46]. Additionally, LAP-induced

lipid peroxidation increases oxidative stress, further harming periodontal tissues [47]. Secondly, abnormal lipid profiles are strongly linked to periodontal inflammation [48, 49], with LAP playing a crucial role in these lipid abnormalities. Furthermore, the link between obesity-related systemic inflammation and a higher prevalence of periodontal disease underscores the influence of LAP [50]. Lastly, periodontal treatment not only improves oral health but may also alleviate systemic inflammation and improve lipid profiles, thereby enhancing overall health [51, 52]. The prevention as well as treatment of oral diseases and related systemic health issues are contingent upon the effective monitoring and management of the LAP.

Recent studies highlight a correlation between oral health and lipids [53, 54], with the relationship between the LAP and oral health being particularly noteworthy. Although research in this area is currently limited, findings suggest that oral health significantly deteriorates with increasing LAP. Notably, factors such as age, education level, and gout significantly influence this correlation. Patients without gout often exhibit superior oral health, and the correlation between LAP and dental health is more significant in this demographic. This may be due to the association of gout with aberrant lipid metabolism [55, 56], resulting in generally poorer oral health among gout patients, which may obscure the impact of rising LAP.

The study reveals that oral health deteriorates rapidly at lower LAP levels but stabilizes once LAP exceeds 83, suggesting a plateau effect where further increases have minimal impact. This threshold effect may stem from both biological and statistical factors. Biologically, the stabilization at $LAP > 83$ could reflect the body's adaptation to excessive lipid accumulation [57, 58]. Given the strong link between obesity and chronic inflammation, systemic inflammation may plateau beyond this threshold, reducing its impact on oral health. Statistically, the small sample size in the $LAP > 83$ group may limit statistical power, while adjustments for multiple covariates could attenuate LAP's direct effect. Additionally, in individuals with high LAP, metabolic comorbidities such as diabetes, hypertension, and cardiovascular disease, along with genetic and lifestyle factors [59, 60], may exert a stronger influence, diminishing LAP's independent role. Further study is essential to elucidate the precise role and processes of LAP in oral health.

Table 2 The results of univariate analysis

Exposure	Mean \pm SD / N(%)	β (95%CI)	P-value
LAP log10 transform	1.54 \pm 0.43	0.42 (0.37, 0.48)	< 0.0001
LAP log10 transformed three groups			
Low	2638 (33.32%)	ref	
Medium	2640 (33.34%)	0.24 (0.18, 0.30)	< 0.0001
High	2640 (33.34%)	0.40 (0.34, 0.46)	< 0.0001
Age	45.51 \pm 19.73	0.01 (0.00, 0.01)	< 0.0001
Age Tertile			
AGET1	2646 (33.22%)	ref	
AGET2	2615 (32.83%)	0.28 (0.22, 0.34)	< 0.0001
AGET3	2705 (33.96%)	0.22 (0.16, 0.28)	< 0.0001
RIP	2.40 \pm 1.59	-0.19 (-0.20, -0.17)	< 0.0001
RIP Tertile			
RIPT1	2655 (33.33%)	ref	
RIPT2	2646 (33.22%)	-0.31 (-0.37, -0.26)	< 0.0001
RIPT3	2665 (33.45%)	-0.71 (-0.76, -0.65)	< 0.0001
Gender			
Male	3894 (48.88%)	ref	
Female	4072 (51.12%)	-0.07 (-0.12, -0.02)	0.0069
Race			
Mexican American	1176 (14.76%)	ref	
Other Hispanic	817 (10.26%)	-0.21 (-0.31, -0.11)	< 0.0001
Non-Hispanic White	3292 (41.33%)	-0.45 (-0.53, -0.38)	< 0.0001
Non-Hispanic Black	1647 (20.68%)	-0.27 (-0.35, -0.19)	< 0.0001
Other Race	1034 (12.98%)	-0.47 (-0.56, -0.38)	< 0.0001
Education Level			
Less Than 9th Grade	694 (8.71%)	ref	
9-11th Grade	999 (12.54%)	-0.06 (-0.16, 0.04)	0.2518
High School Grad/GED or Equivalent	1910 (23.98%)	-0.33 (-0.43, -0.24)	< 0.0001
Some College or AA degree	2467 (30.97%)	-0.63 (-0.72, -0.54)	< 0.0001
College Graduate or above	1896 (23.80%)	-1.00 (-1.09, -0.91)	< 0.0001
Diabetes			
YES	839 (10.53%)	ref	
NO	6947 (87.21%)	-0.28 (-0.36, -0.19)	< 0.0001
Borderline	180 (2.26%)	-0.13 (-0.31, 0.05)	0.158
Hypertension			
YES	2609 (32.75%)	ref	
NO	5357 (67.25%)	-0.22 (-0.27, -0.17)	< 0.0001
Coronary Heart Disease			
YES	270 (3.39%)	ref	
NO	7696 (96.61%)	-0.27 (-0.41, -0.13)	0.0001
Hypercholesterolemia			
YES	2460 (30.88%)	ref	
NO	5506 (69.12%)	-0.10 (-0.16, -0.05)	0.0002
Gout			
YES	1848 (23.20%)	ref	
NO	6118 (76.80%)	-0.19 (-0.24, -0.13)	< 0.0001
Stroke			
YES	241 (3.03%)	ref	
NO	7725 (96.97%)	-0.21 (-0.36, -0.07)	0.0035
Cancer Or Malignancy			
YES	647 (8.12%)	ref	
NO	7319 (91.88%)	0.09 (-0.00, 0.18)	0.053
Alcohol Use			

Table 2 (continued)

Exposure	Mean ± SD / N(%)	β (95%CI)	P-value
Never drinking	998 (12.53%)	ref	
Moderate drinking	6732 (84.51%)	-0.00 (-0.08, 0.07)	0.9458
Heavy drinking	236 (2.96%)	0.03 (-0.13, 0.19)	0.6907
Cigarette Use			
Never smoker	4225 (53.04%)	ref	
Former smoker	2379 (29.86%)	0.10 (0.05, 0.16)	0.0002
Current smoker	1362 (17.10%)	0.65 (0.58, 0.71)	< 0.0001

Table 3 Relationship between LAP and self-reported oral health outcomes in different models

Exposure	Unadjusted model	Model 1	Model 2
LAP log10 transform	0.42 (0.37, 0.48) < 0.0001	0.31 (0.25, 0.37) < 0.0001	0.26 (0.20, 0.32) < 0.0001
LAP log10 transformed three groups			
Low	ref	ref	ref
Medium	0.24 (0.18, 0.30) < 0.0001	0.16 (0.10, 0.22) < 0.0001	0.14 (0.08, 0.20) < 0.0001
High	0.40 (0.34, 0.46) < 0.0001	0.24 (0.18, 0.31) < 0.0001	0.21 (0.14, 0.27) < 0.0001

Results in table: β (95%CI) P-value
Outcome variable: self-reported oral health outcomes
Exposure variable: LAP
unadjusted model adjusts for: None
model 1 adjusts for gender, age, race, education level, RIP
model 2 adjusts for gender, age, race, education level, RIP, diabetes, hypertension, coronary heart disease, hypercholesterolemia, gout, stroke, cancer or malignancy, alcohol use and cigarette use




Fig. 2 The non-linear relationship between LAP and self-reported oral health outcomes. The solid red line illustrates the smooth curve fit between variables, with blue bands indicating the 95% confidence interval, while adjusting for confounding factors including gender, age, race, education level, the ratio of family income to poverty (RIP), diabetes, hypertension, coronary heart disease, hypercholesterolemia, gout, stroke, cancer or malignancy, alcohol use, and cigarette use

Table 4 Analysis of the threshold effect of LAP and self-reported oral health outcomes

Outcome:	Self-reported oral health outcomes
A straight-line effect	0.00 (0.00, 0.00) < 0.0001
Folding point (K)	83
< K Segment Effect 1	0.00 (0.00, 0.00) < 0.0001
> K Segment effect 2	0.00 (-0.00, 0.00) 0.1648
Difference in effect between 2 and 1	-0.00 (-0.00, -0.00) < 0.0001
Predicted value of the equation at the fold point	3.20 (3.15, 3.25)
Log-likelihood ratio test (p)	< 0.001

Results in table: β (95%CI) P-value
Outcome variable: self-reported oral health outcomes
Exposure variable: LAP
Adjusted variable: gender, age, race, education level, RIP, diabetes, hypertension, coronary heart disease, hypercholesterolemia, gout, stroke, cancer or malignancy, alcohol use and cigarette use

Addressed within this research is the inaugural demonstration of a correlation between the LAP and oral health. Furthermore, the sample size is substantial and dependable. This analysis was conducted retrospectively and cross-sectionally, limiting our ability to establish a causal relationship between LAP and oral health. Efforts to address numerous confounding variables have been made, yet unaccounted confounders may still affect the connection between LAP and oral health.

Conclusion

In conclusion, a significant association was observed between self-reported oral health outcomes and LAP within the American population, even after controlling for various confounding factors. This study proposes that future research should explore both the potential of LAP as a predictive biomarker for oral health outcomes and its applicability in clinical practice to guide personalized early interventions and prevention strategies.




Fig. 3 The results of subgroup analyses

Abbreviations

LAP Lipid Accumulation Product

NHANES National Health and Nutrition Examination Survey

WC Waist Circumference

TG Triglycerides

PCOS Polycystic Ovarian Syndrome

CI Confidence Interval

MECs Mobile Examination Centers

RIP Ratio of Family Income to Poverty

OHQ Oral Health Questionnaire

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12944-025-02543-4>.

Supplementary Material 1: Attached Fig. 1 The association between LAP and self-reported oral health outcomes stratified by gender. In the diagram, red represents males, and blue represents females. Attached Fig. 2 The association between LAP and self-reported oral health outcomes stratified by age. In the diagram, red represents the low age group (AGET1), green represents the middle age group (AGET2), and blue

represents the high age group (AGET3). Attached Fig. 3 The association between LAP and self-reported oral health outcomes stratified by Education Level. In the diagram, red represents "Less Than 9th Grade," yellow represents "9-11th Grade," green represents "High School Grad/GED or Equivalent," blue represents "Some College or AA degree," and purple represents "College Graduate or above.". Attached Fig. 4 The association between LAP and self-reported oral health outcomes stratified by Race. In the diagram, red represents "Mexican American," yellow represents "Other Hispanic," green represents "Non-Hispanic White," blue represents "Non-Hispanic Black," and purple represents "Other Race.". Attached Fig. 5 The association between LAP and self-reported oral health outcomes stratified by RIP. In the diagram, red represents the low RIP group (RIPT1), green represents the middle RIP group (RIPT2), and blue represents the high RIP group (RIPT3). Attached Fig. 6 The association between LAP and self-reported oral health outcomes stratified by Diabetes. In the diagram, red represents "YES," green represents "NO," and blue represents "Borderline.". Attached Fig. 7 The association between LAP and self-reported oral health outcomes stratified by Hypertension. In the diagram, red represents "YES," and blue represents "NO.". The association between LAP and self-reported oral health outcomes stratified by Coronary Heart Disease. In the diagram, red represents "YES," and blue represents "NO.". Attached Fig. 9 The association between LAP and self-reported oral health outcomes stratified by Hypercholesterolemia. In the diagram, red represents "YES," and blue repre-

sents "NO.". Attached Fig. 10 The association between LAP and self-reported oral health outcomes stratified by Gout. In the diagram, red represents "YES," and blue represents "NO.". Attached Fig. 11 The association between LAP and self-reported oral health outcomes stratified by Stroke. In the diagram, red represents "YES," and blue represents "NO.". Attached Fig. 12 The association between LAP and self-reported oral health outcomes stratified by Cancer Or Malignancy. In the diagram, red represents "YES," and blue represents "NO.". Attached Fig. 13 The association between LAP and self-reported oral health outcomes stratified by Alcohol Use. In the diagram, red represents "never drinking," green represents "moderate drinking," and blue represents "heavy drinking.". Attached Fig. 14 The association between LAP and self-reported oral health outcomes stratified by Cigarette Use. In the diagram, red represents "never smoker," green represents "former smoker," and blue represents "current smoker."

Acknowledgements

The author is very grateful to the data providers of the study. I would like to express my gratitude to Kenneth Sayson and A. M. Abd El-Aty for their review and assistance with the article.

Author contributions

(1) LSN was involved in the study design, literature review, data analysis, and manuscript preparation. (2) YW was involved in the development of the concept and was responsible for the critical review of the manuscript. (3) FXH carried out the data collection. (4) DJF and LJL were involved in the development of the concept and were responsible for the critical review of the manuscript.

Funding

This study was funded by the Health Commission of Hebei Province (20240102).

Data availability

Publicly available datasets were analyzed in this study. This data can be found here: www.cdc.gov/nchs/nhanes/.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 16 November 2024 / Accepted: 19 March 2025

Published online: 04 April 2025

References

1. Tellechea ML, Aranguren F, Martínez-Larrad MT, Serrano-Ríos M, Taverna MJ, Frechtel GD. Ability of lipid accumulation product to identify metabolic syndrome in healthy men from Buenos Aires. *Diabetes Care*. 2009;32(7):e85.
2. Wehr E, Gruber HJ, Giuliani A, Möller R, Pieber TR, Obermayer-Pietsch B. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. *J Clin Endocrinol Metab*. 2011;96(6):E986–990.
3. Taverna MJ, Martínez-Larrad MT, Frechtel GD, Serrano-Ríos M. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. *Eur J Endocrinol*. 2011;164(4):559–67.
4. Wakabayashi I, Daimon T. A strong association between lipid accumulation product and diabetes mellitus in Japanese women and men. *J Atheroscler Thromb*. 2014;21(3):282–8.
5. Liu T, Lu W, Zhao X, Yao T, Song B, Fan H, et al. Relationship between lipid accumulation product and new-onset diabetes in the Japanese population: a retrospective cohort study. *Front Endocrinol (Lausanne)*. 2023;14:1181941.
6. Hosseinpahan F, Barzin M, Mirbolouk M, Abtahi H, Cheraghi L, Azizi F. Lipid accumulation product and incident cardiovascular events in a normal weight population: Tehran lipid and glucose study. *Eur J Prev Cardiol*. 2016;23(2):187–93.
7. Uysal E, Tammo O, Soylemez E, Incebiyik M, Filiz D, Alci M. Significance of measuring anthropometric and atherogenic indices in patients with polycystic ovary syndrome. *BMC Endocr Disord*. 2024;24(1):160.
8. Yu ZW, Li X, Wang Y, Fu YH, Gao XY. Association between lipid accumulation product and mild cognitive impairment in patients with type 2 diabetes. *J Alzheimers Dis*. 2020;77(1):367–74.
9. Macut D, Tziomalos K, Božić-Antić I, Bjekić-Macut J, Katsikis I, Papadakis E, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. *Hum Reprod*. 2016;31(6):1347–53.
10. SHIN JY. Lipid accumulation product and sarcopenia in Korean patients with type 2 diabetes. *Diabetes*. 2018;67(Supplement1):2066–P.
11. Herrera D, Sanz M, Shapira L, Brotons C, Chapple I, Frese T, et al. Association between periodontal diseases and cardiovascular diseases, diabetes and respiratory diseases: consensus report of the joint workshop by the European federation of periodontology (EFP) and the European arm of the world organization of family Doctors (WONCA Europe). *J Clin Periodontol*. 2023;50(6):819–41.
12. Ayuthaya BIN, Lertpimonchai A, Samaranayake L, Vathesatogkit P, Thienpramuk L, Wisitrasameewong W, et al. The potential effect of periodontal disease on the development of metabolic syndrome: A 10-Year observational study in a Thai adult cohort. *J Clin Periodontol*. 2025;52(3):339–52.
13. Kaur S, White S, Bartold PM. Periodontal disease and rheumatoid arthritis: a systematic review. *J Dent Res*. 2013;92(5):399–408.
14. Yu B, Wang CY. Osteoporosis and periodontal diseases - An update on their association and mechanistic links. *Periodontol 2000*. 2022;89(1):99–113.
15. Michaud DS, Fu Z, Shi J, Chung M. Periodontal disease, tooth loss, and cancer risk. *Epidemiol Rev*. 2017;39(1):49–58.
16. Michaud DS, Liu Y, Meyer M, Giovannucci E, Josphura K. Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. *Lancet Oncol*. 2008;9(6):550–8.
17. Moreno C, Bybee E, Tellez Freitas CM, Pickett BE, Weber KS. Meta-Analysis of two human RNA-seq datasets to determine periodontitis diagnostic biomarkers and drug target candidates. *Int J Mol Sci*. 2022;23(10):5580.
18. Parveen S, Alhazmi YA. Impact of intermittent fasting on metabolic syndrome and periodontal Disease-A suggested preventive strategy to reduce the public health burden. *Int J Environ Res Public Health*. 2022;19(21):14536.
19. Prince Y, Davison GM, Davids SFG, Erasmus RT, Kengne AP, Graham LM, et al. The relationship between the oral microbiota and metabolic syndrome. *Biomedicines*. 2022;11(1):3.
20. Shao Q, Li J, Wu Y, Liu X, Wang N, Jiang Y, et al. Enhanced predictive value of lipid accumulation product for identifying metabolic syndrome in the general population of China. *Nutrients*. 2023;15(14):3168.
21. Li H, Zhang Y, Luo H, Lin R. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the united States adults. *Front Endocrinol (Lausanne)*. 2022;13:977625.
22. Iranpour S, Sabour S. Inverse association between caffeine intake and depressive symptoms in US adults: data from National health and nutrition examination survey (NHANES) 2005–2006. *Psychiatry Res*. 2019;271:732–9.
23. Buhlin K, Gustafsson A, Andersson K, Håkansson J, Klinge B. Validity and limitations of self-reported periodontal health. *Community Dent Oral Epidemiol*. 2002;30(6):431–7.
24. Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Beck JD, et al. Self-reported measures for surveillance of periodontitis. *J Dent Res*. 2013;92(11):1041–7.
25. Khader Y, Alhabashneh R, Alhersh F. Development and validation of a self-reported periodontal disease measure among Jordanians. *Int Dent J*. 2015;65(4):203–10.
26. Meisel P, Holtfreter B, Völzke H, Kocher T. Self-reported oral health predicts tooth loss after five and ten years in a population-based study. *J Clin Periodontol*. 2018;45(10):1164–72.
27. Abboud HM, Hinz J, Cherukara G, Macfarlane TV. Validity of Self-Reported periodontal disease: A systematic review and Meta-Analysis. *J Periodontol*. 2016;87(12):1474–83.
28. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the united States, 2005 to 2014. *JAMA*. 2016;315(21):2284–91.
29. You Y, Chen Y, Fang W, Li X, Wang R, Liu J, et al. The association between sedentary behavior, exercise, and sleep disturbance: A mediation analysis of inflammatory biomarkers. *Front Immunol*. 2022;13:1080782.

30. Kahn HS. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. *Diabetes Care*. 2006;29(1):151–3.
31. Song J, Zhao Y, Nie S, Chen X, Wu X, Mi J. The effect of lipid accumulation product and its interaction with other factors on hypertension risk in Chinese Han population: A cross-sectional study. *PLoS ONE*. 2018;13(6):e0198105.
32. Dabhadkar KC, Deshmukh A, Badheka A, Mehta J, Abstract. 17680: Association of Lipid Accumulation Product with All-Cause, Cardiovascular or Ischemic Heart Disease Mortality: The National Health and Nutrition Examination Survey. *Circulation [Internet]*. 2012 Nov 20 [cited 2024 Nov 1]; Available from: <https://www.semanticscholar.org/paper/Abstract-17680%3A-Association-of-Lipid-Accumulation-Dabhadkar-Deshmukh/cde9cb266b174d225bcfb8d64e1a3f2bda259792>
33. Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. *PLoS ONE*. 2012;7(7):e39504.
34. Nunes SH, Nogueira Saad MA, da Cruz Filho RA, Jorge AJL, Santos MMSD, de Martins W. Is lipid accumulation product a better cardiovascular risk predictor in elderly individuals than anthropometric measures? *Rev Port Cardiol (Engl Ed)*. 2021;40(8):539–44.
35. Saad MJA, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. *Physiol (Bethesda)*. 2016;31(4):283–93.
36. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. *Am J Physiol Cell Physiol*. 2021;320(3):C375–91.
37. Pathak JL, Yan Y, Zhang Q, Wang L, Ge L. The role of oral Microbiome in respiratory health and diseases. *Respir Med*. 2021;185:106475.
38. Yuwanati M, Gondivkar S, Sarode SC, Gadgil A, Desai A, Mhaske S, et al. Oral health-related quality of life in oral cancer patients: systematic review and meta-analysis. *Future Oncol*. 2021;17(8):979–90.
39. Ford PJ, Rich AM. Tobacco use and oral health. *Addiction*. 2021;116(12):3531–40.
40. Hopkins S, Gajagowni S, Qadeer Y, Wang Z, Virani SS, Meurman JH, et al. Oral health and cardiovascular disease. *Am J Med*. 2024;137(4):304–7.
41. Kudiyirickal MG, Pappachan JM. Diabetes mellitus and oral health. *Endocrine*. 2015;49(1):27–34.
42. Shaddox LM, Wiedey J, Calderon NL, Magnusson I, Bimstein E, Bidwell JA, et al. Local inflammatory markers and systemic endotoxin in aggressive periodontitis. *J Dent Res*. 2011;90(9):1140–4.
43. Shi D, Meng H, Xu L, Zhang L, Chen Z, Feng X, et al. Systemic inflammation markers in patients with aggressive periodontitis: a pilot study. *J Periodontol*. 2008;79(12):2340–6.
44. Allin N, Cruz-Almeida Y, Velsko I, Vovk A, Hovemcamp N, Harrison P, et al. Inflammatory response influences treatment of localized aggressive periodontitis. *J Dent Res*. 2016;95(6):635–41.
45. Shaddox LM, Gonçalves PF, Vovk A, Allin N, Huang H, Hou W, et al. LPS-induced inflammatory response after therapy of aggressive periodontitis. *J Dent Res*. 2013;92(8):702–8.
46. Kaur K, Turner A, Jones P, Sculley D, Veysey M, Lucock M, et al. A Cross-Sectional study of Bitter-Taste receptor genotypes, oral health, and markers of oral inflammation. *Oral*. 2021;1(2):122–38.
47. Akalin FA, Baltacıoğlu E, Alver A, Karabulut E. Lipid peroxidation levels and total oxidant status in serum, saliva and gingival crevicular fluid in patients with chronic periodontitis. *J Clin Periodontol*. 2007;34(7):558–65.
48. Mikami R, Mizutani K, Matsuyama Y, Matsuura T, Kido D, Takeda K, et al. Association between periodontal inflammation and serum lipid profile in a healthy population: A cross-sectional study. *J Periodontol Res*. 2021;56(6):1037–45.
49. Techatanawat S, Komchornrit A. Association of lipid profile and body mass index with periodontal status in patients with dyslipidemia with and without lipid-lowering medication: A Cross-sectional study. *Oral Health Prev Dent*. 2021;19:149–56.
50. Thanakun S, Pornprasertsuk-Damrongsri S, Izumi Y. Increased oral inflammation, leukocytes, and leptin, and lower adiponectin in overweight or obesity. *Oral Dis*. 2017;23(7):956–65.
51. Fentoğlu Ö, Sözen T, Öz S, Kale B, Sönmez Y, Öztürk Tonguç M, et al. Short-term effects of periodontal therapy as an adjunct to anti-lipemic treatment. *Oral Dis*. 2010;16(7):648–54.
52. Oz SG, Fentoglu O, Kilicarslan A, Guven GS, Tanrtover MD, Aykac Y, et al. Beneficial effects of periodontal treatment on metabolic control of hypercholesterolemia. *South Med J*. 2007;100(7):686–91.
53. Sanz M, Marco Del Castillo A, Jepsen S, Gonzalez-Juanatey JR, D'Aiuto F, Boucharde P, et al. Periodontitis and cardiovascular diseases: consensus report. *J Clin Periodontol*. 2020;47(3):268–88.
54. Song TJ, Kim JW, Kim J. Oral health and changes in lipid profile: A nationwide cohort study. *J Clin Periodontol*. 2020;47(12):1437–45.
55. Li T, Zhang H, Wu Q, Guo S, Hu W. Association between triglyceride glycemic index and gout in US adults. *J Health Popul Nutr*. 2024;43(1):115.
56. Kvasnička A, Friedecký D, Brumarová R, Pavlíková M, Pavelcová K, Mašíňová J, et al. Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment. *Arthritis Res Ther*. 2023;25(1):234.
57. Heber D. An integrative view of obesity. *Am J Clin Nutr*. 2010;91(1):S280–3.
58. Astrup A, Buemann B, Western P, Toubro S, Raben A, Christensen NJ. Obesity as an adaptation to a high-fat diet: evidence from a cross-sectional study. *Am J Clin Nutr*. 1994;59(2):350–5.
59. Morelli T, Agler CS, Divaris K. Genomics of periodontal disease and tooth morbidity. *Periodontol 2000*. 2020;82(1):143–56.
60. Spahr A, Divnic-Resnik T. Impact of health and lifestyle food supplements on periodontal tissues and health. *Periodontol 2000*. 2022;90(1):146–75.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.